CD44 and breast cancer: After two weeks, MDA-MB-231 cells transfected with the control siRNA could generate tumors, while MDA-MB-231 cells transfected with CD44 siRNA or ALDH1 siRNA could not (Fig. 6D), indicating that the suppression of CD44 and ALDH1 both reduced the tumorigenicity of breast cancer cells.